Abstract
In the past decades, many efforts were undertaken to develop ligands for the adenosine receptors, with the purpose to individuate agonists and antagonists affinity and selectivity for each subtypes, namely A1, A2A, A2B, and A3. These intense studies allowed a deeper knowledge of the nature and, moreover, of the pathophysiological roles of all the adenosine receptor subtypes. In particular, the involvement of the A2A adenosine receptor subtype in some physiological mechanisms in the brain, that could be related to important diseases such as the Parkinson’s disease, encouraged the research in this field. Particular attention was given to the antagonists endowed with high affinity and selectivity since they could have a real employment in the treatment of Parkinson’s disease, and some compounds, such as istradefylline, preladenant and tozadenant, are already studied in clinical trials. Actually, the role of A2A antagonists in Parkinson’s disease is becoming contradictory due to contrasting results in the last studies, but, at the same time, new possible employments are emerging for this class of antagonists in cancer pathologies as much interesting to legitimate further efforts in the research of A2A ligands.
Keywords: A2A antagonists, adenosine, Parkinson’s disease, cancer, heterotetramers, immunosuppression.
Mini-Reviews in Medicinal Chemistry
Title:A2A Adenosine Receptor Antagonists as Therapeutic Candidates: Are They Still an Interesting Challenge?
Volume: 18 Issue: 14
Author(s): Barbara Cacciari*, Giampiero Spalluto and Stephanie Federico
Affiliation:
- Dipartimento di Scienze Chimiche e Farmaceutiche, Università di Ferrara, Via Fossato di Mortara 17-19, I-44121 Ferrara,Italy
Keywords: A2A antagonists, adenosine, Parkinson’s disease, cancer, heterotetramers, immunosuppression.
Abstract: In the past decades, many efforts were undertaken to develop ligands for the adenosine receptors, with the purpose to individuate agonists and antagonists affinity and selectivity for each subtypes, namely A1, A2A, A2B, and A3. These intense studies allowed a deeper knowledge of the nature and, moreover, of the pathophysiological roles of all the adenosine receptor subtypes. In particular, the involvement of the A2A adenosine receptor subtype in some physiological mechanisms in the brain, that could be related to important diseases such as the Parkinson’s disease, encouraged the research in this field. Particular attention was given to the antagonists endowed with high affinity and selectivity since they could have a real employment in the treatment of Parkinson’s disease, and some compounds, such as istradefylline, preladenant and tozadenant, are already studied in clinical trials. Actually, the role of A2A antagonists in Parkinson’s disease is becoming contradictory due to contrasting results in the last studies, but, at the same time, new possible employments are emerging for this class of antagonists in cancer pathologies as much interesting to legitimate further efforts in the research of A2A ligands.
Export Options
About this article
Cite this article as:
Cacciari Barbara *, Spalluto Giampiero and Federico Stephanie , A2A Adenosine Receptor Antagonists as Therapeutic Candidates: Are They Still an Interesting Challenge?, Mini-Reviews in Medicinal Chemistry 2018; 18 (14) . https://dx.doi.org/10.2174/1389557518666180423113051
DOI https://dx.doi.org/10.2174/1389557518666180423113051 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CRISPR-cas System as a Genome Engineering Platform: Applications in Biomedicine and Biotechnology
Current Gene Therapy Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients
Current Pharmaceutical Biotechnology New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer
Current Pharmaceutical Design Metabolic Profiling in Disease Diagnosis, Toxicology and Personalized Healthcare
Current Pharmaceutical Biotechnology <i>In Silico</i> Study of Potential Cross-Kingdom Plant MicroRNA Based Regulation in Chronic Myeloid Leukemia
Current Pharmacogenomics and Personalized Medicine Cilostazol as a Unique Antithrombotic Agent
Current Pharmaceutical Design Targeting the Endocannabinoid System for the Treatment of Cancer – A Practical View
Current Topics in Medicinal Chemistry Interleukin-15 in Gene Therapy of Cancer
Current Gene Therapy Pyrrolizidine Alkaloids and their Biological Properties from Indian Heliotropium Species
Current Bioactive Compounds HtrA Serine Proteases as Potential Therapeutic Targets in Cancer
Current Cancer Drug Targets Optimizing Tumor-Reactive γδT Cells for Antibody-Based Cancer Immunotherapy
Current Molecular Medicine Multiple Target-Specific Molecular Imaging Agents Detect Liver Cancer in a Preclinical Model
Current Molecular Medicine Is There a Role for Antioxidants in the Prevention of Infection-Associated Carcinogenesis and in the Treatment of Infection-Driven Tumors?
Current Topics in Medicinal Chemistry Advancements in Non-steroidal Antiandrogens as Potential Therapeutic Agents for the Treatment of Prostate Cancer
Mini-Reviews in Medicinal Chemistry The Development of Cytokine Receptor Antagonists as Potential Therapeutic Agents for the Myeloproliferative Disorders
Current Pharmaceutical Design The Role of Antihistamine Drugs in Allergic Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Synthesis and Antiproliferative Assay of Norcantharidin Derivatives in Cancer Cells
Medicinal Chemistry Combined Treatment with PPAR-γ Agonists in Pancreatic Cancer: A Glimmer of Hope for Cancer Therapy?
Current Cancer Drug Targets IAPs as a Target for Anticancer Therapy
Current Cancer Drug Targets Is DNA Minor Groove Binding Crucial for Biological Activity of Triazoloacridinones with Cytotoxic and Antitumour Properties?
Letters in Drug Design & Discovery